differentiated antibiotics

Cempra Announces Full Exercise of Additional Share Option and Completion of the Public Offering of Common Stock

CHAPEL HILL, N.C., Jan. 13, 2015 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has completed its previously announced underwritten public offering of 5,250,000 shares of common stock, plus an additional 787,500 shares issued pursuant to the full exercise by the underwriters of their option to purchase additional shares at a public offering price of $24.50 per share.

 

Cempra Prices Public Offering of Common Stock

CHAPEL HILL, N.C., Jan. 7, 2015 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has priced an underwritten public offering of 5,250,000 shares of its common stock at a price of $24.50 per share for aggregate gross proceeds of approximately $128.6 million.